Anti-MAGE-1 (Melanoma-associated Antigen 1, MAGE-1 Antigen, Cancer/testis Antigen, CTA)

Recognizes a protein of 42-46kD, identified as MAGE-1. This monoclonal antibody does not cross-react with MAGE- 2, -3, -4, -6 -9, -10, -or -12 protein. Human malignant neoplasms carry rejection antigens that are recognized by the patients' autologous, tumor directed and specific, cytolytic, CD8+ T lymphocyte clones (CTL). The MAGE family of genes codes an important group of antigens. It was identified that melanomas and primary glial brain tumors express common melanoma associated antigens (MAAs). Because MAGE-1 is expressed on a significant proportion of human neoplasms of various histological types (melanoma, brain tumors of glial origin, neurobla stoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, renal cell carcinomas) and not on normal tissues, the encoded antigen may serve as a marker of early detection and target for cancer immunotherapy. Applications: Suitable for use in ELISA, Western Blot, Flow Cytometry, Immunofluorescence, Immunoprecipitation and Immunohistochemistry. Other applications not tested. Recommended Dilution: Western Blot: 0.5-1ug/ml, Flow Cytometry: 0.5-1ug/10e6 cells, Immunofluorescence: 1-2ug/ml, Immunoprecipitation: 1-2ug/500ug protein lysate, Immunohistochemistry (Frozen & Formalin fixed paraffin embedded): 0.5-1ug/ml/30min @ RT, Optimal dilutions to be determined by the researcher. Positive Control: Melanoma cell lines. Melanomas, gliomas, neuroblastoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, and renal cell carcinomas. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.